Combination of PARP inhibitors and c-MET may benefit breast cancer patients

[News]

Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers.

More... (http://www.news-medical.net/news/20160119/Combination-of-PARP-inhibitors-and-c-MET-may-benefit-breast-cancer-patients.aspx)